Skip to main content

Together we are beating cancer

Donate now

Search Results: PARP inhibitor

Showing 12 out of 133 results
Patient photo

How researchers supported by Cancer Research UK pioneered the development of PARP inhibitors. How researchers supported by Cancer Research UK pioneered the development of PARP inhibitors.

by Liam Drew | Research Feature | 24 September 2020

24 September 2020

PARP and inhibitor

Olaparib is the first PARP inhibitor to move closer to licensing in Europe. What is it, how does it work, and when will it be available in the UK? Olaparib is the first PARP inhibitor to move closer to licensing in Europe. What is it, how does it work, and when will it be available in the UK?

by Kat Arney | Analysis | 24 October 2014

24 October 2014

The first episode features Ruth Plummer. Ruth is Professor of Experimental Cancer Medicine at Newcastle University and Director of the CRUK Newcastle Cancer Centre. She talks about how the DNA repair inhibition field has changed over 20 years, her instrumental role in the development of the PARP inhibitor Rucaparib and why work/life balance is so important for the future of research life. The first episode features Ruth Plummer. Ruth is Professor of Experimental Cancer Medicine at Newcastle University and Director of the CRUK Newcastle Cancer Centre. She talks about how the DNA repair inhibition field has changed over 20 years, her instrumental role in the development of the PARP inhibitor Rucaparib and why work/life balance is so important for the future of research life.

by Phil Prime | Podcast | 4 February 2022

4 February 2022

This entry is part 1 of 11 in the series Cancer Research Matters - series 1
Glioblastoma cells seen through a microscope.

We've helped double brain tumour survival over the past 40 years. Now, researchers are combining some of our most successful drugs, temozolomide and PARP inhibitors, to make glioblastoma treatment more effective. We've helped double brain tumour survival over the past 40 years. Now, researchers are combining some of our most successful drugs, temozolomide and PARP inhibitors, to make glioblastoma treatment more effective.

by Tim Gunn | Analysis | 13 February 2023

13 February 2023

Our scientists have been at the forefront of PARP inhibitor research and development. Here we share the story of rucaparib. Our scientists have been at the forefront of PARP inhibitor research and development. Here we share the story of rucaparib.

by Cancer Research UK | Research Feature | 21 July 2017

21 July 2017

Cancer Research UK logo

Cancer Research UK scientists at Newcastle University and researchers based at Harvard University have found that blocking a key component of the DNA repair process could extend the use of a new range of 'smart' cancer drugs called PARP inhibitors. The research is published in Nature Medicine today. Cancer Research UK scientists at Newcastle University and researchers based at Harvard University have found that blocking a key component of the DNA repair process could extend the use of a new range of 'smart' cancer drugs called PARP inhibitors. The research is published in Nature Medicine today.

by Cancer Research UK | News | 26 June 2011

26 June 2011

Cancer Research UK logo

Scientists have developed a new test to select which patients with ovarian cancer will benefit from new drugs called PARP inhibitors, according to research presented at the NCRI Cancer Conference in Liverpool. Scientists have developed a new test to select which patients with ovarian cancer will benefit from new drugs called PARP inhibitors, according to research presented at the NCRI Cancer Conference in Liverpool.

by The National Cancer Research Institute (NCRI) | News | 8 November 2010

8 November 2010